Top Stock to Buy & Hold for Decade

The Case for Beaten-Down Stocks: Why TransMedics, Viking Therapeutics, and Roku Could Be Decade-Long Winners
Wall Street loves a comeback story almost as much as it loves overreacting to bad news. That’s where beaten-down stocks come in—those unloved, oversold tickers that get tossed in the bargain bin despite having solid fundamentals. Think of them as the thrift-store Levi’s of the investing world: slightly scuffed but still premium denim. This article digs into three such stocks—TransMedics Group (NASDAQ: TMDX), Viking Therapeutics (NASDAQ: VKTX), and Roku (NASDAQ: ROKU)—and why their recent stumbles might actually be the perfect setup for patient investors.

The Allure of the Underdog

Every market cycle has its casualties, but not all of them deserve their fate. Beaten-down stocks often suffer from temporary setbacks—a missed earnings target, sector-wide panic, or just plain bad PR—while their long-term potential remains intact. The key is spotting the difference between a sinking ship and a diamond in the rough.
Take the healthcare sector, where regulatory hiccups and clinical trial delays can tank even the most promising biotech stocks overnight. Or streaming, where competition is brutal and profitability often takes a backseat to growth. Yet, history shows that companies with innovative tech, durable moats, and growing addressable markets tend to bounce back. That’s the thesis behind holding TransMedics, Viking Therapeutics, and Roku for the long haul.

TransMedics Group: Revolutionizing Organ Transplants (and Maybe Your Portfolio)

TransMedics Group isn’t just another med-tech company—it’s a potential game-changer in organ transplantation. Its Organ Care System (OCS) keeps donor organs alive outside the body longer, tackling one of healthcare’s most critical bottlenecks. Despite this, the stock has nosedived 31% in six months. Why? Blame short-term jitters over reimbursement hurdles and a slower-than-expected rollout.
But here’s the sleuth-worthy clue: the global organ transplant market is projected to hit $27 billion by 2029, and TransMedics is the only player with a portable, all-in-one perfusion system. Competitors are stuck in the 20th century with ice-packed coolers. With FDA approvals expanding and international adoption growing, this dip could be a gift for investors willing to wait out the noise.

Viking Therapeutics: Biotech’s Rollercoaster Ride to Riches

Viking Therapeutics was the biotech darling of 2024, thanks to its promising NASH (fatty liver disease) and obesity drug candidates. Then 2025 happened. The stock cratered 35% YTD after rival Eli Lilly unveiled competing data, sparking a sector-wide sell-off. Classic case of Wall Street throwing the baby out with the bathwater.
But dig deeper: Viking’s lead drug, VK2735, still has best-in-class potential, with mid-stage trials showing superior weight loss results to early versions of Ozempic. Meanwhile, its XLH treatment could carve out a niche in rare diseases. Biotech investing isn’t for the faint-hearted—volatility comes standard—but Viking’s pipeline is too compelling to ignore. If even one drug gets commercialized, today’s pullback will look like a Black Friday steal.

Roku: Streaming’s Unprofitable (But Unstoppable) Juggernaut

Let’s address the elephant in the room: Roku isn’t profitable. Revenue growth has slowed, and competitors like Amazon Fire TV and Google’s Chromecast are lurking. But before you write it off, consider this: Roku dominates U.S. streaming with a 42% market share, and cord-cutting isn’t slowing down.
The bull case hinges on two things: advertising and international expansion. Roku’s ad-supported model thrives as viewers ditch pricey subscriptions, and its recent moves into markets like Germany and Brazil could unlock new growth. Sure, the stock’s been clobbered, but remember—Netflix traded single digits once too. For investors betting on streaming’s long-term shift, Roku’s current woes might just be a plot twist.

Patience Pays (If You Pick Wisely)

Beaten-down stocks aren’t for everyone. They require stomach-churning volatility tolerance and a Sherlock-level eye for separating temporary pain from terminal decline. But for those willing to dig, the rewards can be massive. TransMedics, Viking, and Roku all share critical traits:

Of course, risks abound—clinical trials fail, streaming wars intensify, and economic downturns happen. Diversification and due diligence are non-negotiable. But for investors with a decade-long horizon, these stocks offer a rare combo of high upside and margin of safety. Just don’t expect a smooth ride. After all, the best thrift-store finds usually need a little cleaning up.